Overview

Effect of Tebipenem on Normal Human Intestinal Microbiota

Status:
Completed
Trial end date:
2021-04-06
Target enrollment:
Participant gender:
Summary
The overall purpose of this study is to support the development of an oral formulation of TBPM-PI-HBr by assessing the potential ecological effects of tebipenem on the normal intestinal microbiota as compared to the effects of oral amoxicillin-clavulanate.
Phase:
Phase 1
Details
Lead Sponsor:
Spero Therapeutics
Collaborator:
Iqvia Pty Ltd
Treatments:
Amoxicillin
Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acid
Clavulanic Acids